NCT02919644View on ClinicalTrials.gov

Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 2, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2031

Conditions
Stage IV Colorectal CancerCurative Resection
Interventions
BIOLOGICAL

autologous dendritic cells loaded with autologous tumour homogenate

Each vaccine dose consists of 10\_7 autologous dendritic cells loaded with autologous tumor homogenate

DRUG

IL2

Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days

Trial Locations (2)

47014

RECRUITING

UO Immunoterapia e Laboratorio TCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l IRCCS, Meldola

Unknown

NOT_YET_RECRUITING

CRO-IRCCS Aviano, Aviano

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER